Larry Luxner, senior correspondent for Rare Disease Advisor, interviews Amir London, CEO of Israel's Kamada — a major biopharmaceutical company that already has an FDA-approved therapy for alpha-1 antitrypsin deficiency, and is now pursuing an inhaled AAT drug for the same disease.
All content for Rare Care Podcast is the property of Rare Care Podcast and is served directly from their servers
with no modification, redirects, or rehosting. The podcast is not affiliated with or endorsed by Podjoint in any way.
Larry Luxner, senior correspondent for Rare Disease Advisor, interviews Amir London, CEO of Israel's Kamada — a major biopharmaceutical company that already has an FDA-approved therapy for alpha-1 antitrypsin deficiency, and is now pursuing an inhaled AAT drug for the same disease.
Larry Luxner, senior correspondent for Rare Disease Advisor, interviews Amir London, CEO of Israel's Kamada — a major biopharmaceutical company that already has an FDA-approved therapy for alpha-1 antitrypsin deficiency, and is now pursuing an inhaled AAT drug for the same disease.
